Lipolytic Peptides for Controlled Fat Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipolytic agents, such as caffeine, have limitations including difficulty in dosage control due to widespread presence in foods, and adverse effects like heart rate acceleration and physical dependence.
Innovation Solution
Development of short peptides with 5 to 9 amino acids, specifically D-decapeptides, which exhibit remarkable lipolytic activity, outperforming caffeine in efficacy and safety by inducing lipolysis at significantly lower concentrations and with fewer side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If caffeine is used as a lipolytic agent, then lipolysis is stimulated, but adverse effects such as heart rate acceleration and physical dependence occur
Solution Approach 1:
The patent extracts the lipolytic active principle from caffeine and identifies specific peptide sequences (including D-amino acid peptides and modified L-amino acid peptides) that provide lipolysis stimulation without the harmful effects of caffeine. This separation allows retention of the beneficial lipolytic function while eliminating the adverse effects associated with caffeine use.
Solution Approach 2:
The patent changes the chemical structure from caffeine (a stimulant compound) to specific peptide sequences with defined amino acid compositions. This parameter change in molecular structure enables the substance to maintain lipolytic activity while avoiding the pharmacological side effects of caffeine, such as cardiovascular stimulation and dependence.
2Reliability
If caffeine is used to control fat metabolism, then lipolysis is activated, but dosage control becomes difficult due to presence in many foods
Solution Approach 1:
The patent extracts the active lipolytic function from caffeine and formulates it as isolated peptide compounds that can be precisely dosed in pharmaceutical and cosmetic formulations. This eliminates the problem of uncontrollable dosage through dietary intake, as the peptide activity can be accurately controlled in controlled-release formulations.
Solution Approach 2:
The patent creates synthetic peptide versions that replicate the lipolytic effect of caffeine without its dosage control problems. These peptides can be incorporated into controlled-release pharmaceutical formulations, allowing precise dosing independent of dietary consumption patterns.
3Object-affected harmful factors
If short peptides are synthesized to improve safety profile, then adverse effects are reduced, but synthesis complexity increases
Solution Approach 1:
The patent segments the peptide synthesis into modular approaches, identifying specific critical amino acid positions and sequences that are essential for activity. This allows focus on synthesizing only the critical portions with high precision while using standard peptide synthesis methods for the remaining portions, thereby managing complexity.
Solution Approach 2:
The patent employs specific chemical modifications at defined positions (such as D-amino acid substitution at critical positions) to optimize both activity and safety. These targeted parameter changes allow the use of established synthesis methodologies while achieving the desired safety profile, rather than requiring complete redesign of the synthesis approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides demonstrate enhanced lipolytic activity, initiating the lipolysis process earlier and maintaining the effect for longer periods, while allowing for low-dose administration to avoid negative side effects associated with caffeine use.
Implementation Method 1
the peptides of the invention show a remarkable increase of the lipolytic activity... the D-decapeptide of sequence SEQ ID NO: 3... has a remarkable lipolytic activity
Data Source
AI summary
Lipolytic peptides having a length from 5 to 9 amino acids and corresponding to SEQ ID NO: 54 or a salt thereof, wherein: X1 represents W or N; X2 represents P, N, a basic amino acid or a hydrophobic amino acid; X3 and X4 are the same or different and represent A, V, L or I; X5 represents F or P; subindexes “a”, “b”, “c”, “d”, “e”, “f” and “g” are integer numbers independently selected from 0 and 1, provided that two, three, four, five or six of the subindexes “a”, “b”, “c”, “d”, “e”, “f” and “g” represent 1 and the remaining represent “0”. Peptides of sequence SEQ ID NO: 39-46 or any salt thereof. The peptides show improved lipolytic activity when compared with other lipolytic agents, such as caffeine or hexa-39.